Very early in the SARS-CoV-2 pandemic, TMPRSS2 was proposed as a potential drug target due to its important role during viral entry, and many clinical studies have been initiated to investigate the efficacy of these drugs in COVID-19 patients. Here, TMPRSS2 is linked to COVID-19.